Casdin Capital
Casdin Capital is a private, New York-based investment management firm founded in 2012 by Eli Casdin that invests across healthcare, biotechnology, synthetic biology, and technology for institutional investors, family offices, and high-net-worth individuals seeking life sciences exposure.
- Company typePrivate
- Founded2012
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Casdin Capital does
Casdin Capital is a private, New York-based investment management firm founded in 2012 by Eli Casdin that conducts fundamental research and invests across the life sciences value chain, spanning Healthcare, Biotechnology, Synthetic Biology, and Technology subsectors such as life science tools, diagnostics, drug developers, molecular medicine, and data platforms. The firm serves institutional investors, family offices, and high-net-worth individuals seeking specialized exposure to innovative life sciences companies, generating revenue through traditional investment management fees and performance allocations (private placement model) without publicly disclosed pricing.
The firm's core offering is its investment research platform and portfolio construction capabilities rather than a software product. It operates with a deliberately lean 11–50 person team structured around a full C-suite (CIO/Founder Eli Casdin; CFO Lawrence Canzoneri; COO Alexandria Fisk; CMO Kelly Axsom, MD; CCO Angelo Crupi; GC Steve Giordano) plus dedicated research (Suzanne Angell, Shaun Rodriguez PhD), trading (Brad Weisgerber), business development and investor relations (Randy White), and technology (Scott Bryan) functions. Casdin distributes exclusively through direct outreach to qualified purchasers and supports existing LPs via a password-protected member portal carrying quarterly partner letters, coffee talk interviews, and presentation archives.
Recent portfolio activity demonstrates active capital deployment across both private rounds and public-market positions, including disclosed stakes in Relay Therapeutics (~$110 million as of February 2026), GeneDx (200,000 shares worth approximately $11.1 million in June 2026), and 2025–2026 Series B participation in City Therapeutics ($99.5 million, co-led), Beacon Biosignals (oversubscribed at $86 million, then expanded past $97 million), Apella ($80 million), and Adlai Nortye ($140 million PIPE). Casdin frequently co-invests alongside elite healthcare and technology investors including ARCH Venture Partners, Fidelity Management, Viking Global Investors, Sofinnova, Cormorant Asset Management, Google Ventures, General Catalyst, Takeda, and Catalio Capital Management, and is advised by a scientific advisory board including Nobel laureate William G. Kaelin, Jr., MD and other translational medicine experts.
Casdin Capital firmographics
Firmographics- Name
- Casdin Capital
- Legal name
- Casdin Capital, LLC
- Website
- http://www.casdincapital.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Casdin Capital is a private, New York-based investment management firm founded in 2012 by Eli Casdin that invests across healthcare, biotechnology, synthetic biology, and technology for institutional investors, family offices, and high-net-worth individuals seeking life sciences exposure.
- Ownership category
- akta.pro rank
Casdin Capital industry classification
Industry- Product category
- Life Sciences Investment Management
- NAICS
- Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector/Thematic Equity (Active) (FSAAAIAG)
- akta.pro secondary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
Keywords
Where Casdin Capital is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Casdin Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Investment Management: Casdin Capital generates revenue through investment management fees and performance allocations from its life sciences-focused investment strategies, serving institutional investors and high net worth individuals seeking exposure to the healthcare, biotechnology, synthetic biology, and technology sectors.
Distribution channels1 record
Marketing channels3 records
Casdin Capital product offering
Product offeringCore offering
Casdin Capital is a fundamental research-driven investment management firm that builds and manages portfolios concentrated in the life sciences sector, spanning Healthcare, Biotechnology, Synthetic Biology, and Technology. The firm deploys capital across public equities and private venture financings in companies advancing molecular medicine, genomics, diagnostics, and life-sciences information platforms, and serves institutional investors, family offices, and high net worth individuals seeking specialized exposure to the life-sciences investment theme.
Product overview
Casdin Capital is a life sciences investment firm that provides investment management services. The firm does not operate a traditional software product platform. Its offerings consist of investment funds, venture capital activities, and investor relations services including a password-protected member portal containing quarterly partner letters, coffee talk presentations, and investment conference materials.
Differentiator
Problem solved
Functional benefit
Products and services
- Life Sciences Fundamental Research Investment Strategy Fundamental research-driven investment management strategy concentrated on life sciences, covering Healthcare, Biotechnology, Synthetic Biology, and Technology subsectors, and offered to institutional investors, family offices, and high net worth individuals.
- Life Sciences Venture Capital Participations Private venture capital financings into life-sciences companies across molecular medicine, genomics, diagnostics, and life-sciences information platforms, including participation in rounds for City Therapeutics, Beacon Biosignals, Apella, Octave Bioscience, and Adlai Nortye.
- Public Equities Investment in Life Sciences Public equity investments in life-sciences issuers, including significant positions such as the Casdin Capital stake in Relay Therapeutics valued at approximately $110 million and the acquisition of 200,000 shares of GeneDx Holdings Corp valued at approximately $11.1 million.
- Member Portal Investor Communications Password-protected member portal providing existing investors with quarterly partner letters, coffee talk interviews with industry leaders, and presentation archives from Casdin Capital Spotlight events.
Companies that use Casdin Capital
Customer profileSegments1 record
Ideal customer profiles2 records
Casdin Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Casdin Capital partnerships and signals
Strategic signalScale indicators4 records
Recent moves5 records
Expansion highlights5 records
Casdin Capital competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Casdin Capital social profiles
Digital presenceCasdin Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Casdin Capital leadership team
Management profileNumber of profiles
Profiles28 records
Casdin Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Casdin Capital M&A and investment
M&A and investmentM&A
Investments258 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Casdin Capital
What does Casdin Capital do?
Casdin Capital is a fundamental research-driven investment management firm that builds and manages portfolios concentrated in the life sciences sector, spanning Healthcare, Biotechnology, Synthetic Biology, and Technology. The firm deploys capital across public equities and private venture financings in companies advancing molecular medicine, genomics, diagnostics, and life-sciences information platforms, and serves institutional investors, family offices, and high net worth individuals seeking specialized exposure to the life-sciences investment theme.
Is Casdin Capital a public or private company?
Casdin Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Casdin Capital founded?
Casdin Capital was founded in 2012. It employs 11 to 50 people.
Where is Casdin Capital based?
Casdin Capital is headquartered in New York, United States, in the North America region.
How does Casdin Capital make money?
One revenue line is on record: investment Management.
Does Casdin Capital have an API?
No public API is recorded for Casdin Capital.
What industry is Casdin Capital in?
Casdin Capital's product category is Life Sciences Investment Management. Its primary akta.pro industry code is FSAAAIAG, Sector/Thematic Equity (Active), with a secondary code of FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.